Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beta 1,3-1,6 glucan is a naturally occurring polysaccharide derived from the cell wall of the black yeast *Aureobasidium pullulans*. Developed by Nichi Glucan and GN Corporation, it functions as an immunomodulatory adjuvant and biological response modifier. The compound is primarily utilized as a dietary supplement to support immune function in various conditions. Specifically, the **Neu-REFIX** formulation has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for the treatment of Duchenne Muscular Dystrophy (DMD), where it is investigated for its ability to modulate inflammation and potentially slow disease progression. The **Nichi Brite** formulation is used as a supportive adjuvant in patients with gastrointestinal and hepatobiliary cancers, including pancreatic and bile duct cancers. Its mechanism involves the activation of innate immune cells such as macrophages and natural killer (NK) cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta 1,3-1,6 glucan.